Cardiology Self-Assessment Program (CardSAP) (L269229)
ACPE Numbers: Various – see listing below Release Date: November 16, 2026 Expiration Dates: November 16, 2027 Activity Type: Application-based CE Credits: 20.5 contact hours (BPS and ACPE) Activity Fee: $80 (ASHP member); $120 (non-member)
Activity Overview
This course is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 9learning modules (see table below) and provides up to 20.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board-certified pharmacists are eligible to receive up to 20.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCCP.
Learning Activity
Passing Score
Credit Information
Chapter: ACLS Guideline Update
80%
2.0 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-247-H01-P
Chapter: Cardiogenic Shock
80%
4.0 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-248-H01-P
Chapter: Perioperative Drug Management in Cardiac Surgery
80%
2.0 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-249-H01-P
Chapter: Atrial Fibrillation Guideline Update
86%
2.5 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-250-H01-P
Chapter: Cardiometabolic and Lifestyle Interventions for Atrial Fibrillation
93%
1.5 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-244-H01-P
Chapter: Atrial Arrhythmias: Rhythm Control and Ambulatory Monitoring
66%
2.5 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-251-H01-P
Case Series: Bleeding Mitigation in Patients with Atrial Fibrillation
91%
2.5 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-252-H01-P
Chapter: Inpatient Antithrombotic Stewardship
86%
2.0 Contact Hours
BPS: BCCP ACPE: 0217-9999-26-253-H01-P
Chapter: Biostatistics and Literature Evaluation in Antithrombotic Clinical Studies
Account for arrest characteristics and how they affect medication choice and effectiveness within the advanced cardiac life support (ACLS) algorithms.
Delineate the role of non-vasopressor therapies in the treatment of pulseless electrical activity (PEA)/asystole.
Assess the usefulness of antiarrhythmics and their place at various time points within the ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT) algorithm.
Design a comprehensive treatment plan for optimizing patient care after return of spontaneous circulation (ROSC).
Develop alternative treatment algorithms that account for unique clinical circumstances in cardiac arrest.
Classify a patient with decompensated heart failure into a hemodynamic subset of cardiogenic shock (CS) on the basis of signs, symptoms, laboratory values, and hemodynamics obtained through pulmonary artery catheter monitoring.
Design an initial pharmacotherapeutic treatment and monitoring plan for a patient with CS on the basis ofhemodynamic subset.
Assess the usefulness of a treatment approach for CS, including use of diuretics, vasodilators, and inotropes.
Assess the usefulness of mechanical circulatory support devices in the treatment of CS.
Design a comprehensive treatment plan for optimizing the care of patients in CS.
Chapter: Perioperative Drug Management in Cardiac Surgery ACPE #: 0217-9999-26-249-H01-P
Assess anticipated pathophysiologic changes in patients throughout the perioperative phases of care: preoperative, intraoperative, and postoperative.
Apply global guideline recommendations for treatment of patients in the perioperative period.
Design a comprehensive treatment plan for perioperative management of chronic medications.
Prepare and implement a perioperative blood conservation plan.
Apply the updated atrial fibrillation stages to determine appropriate diagnosis and management for a patient.
Estimate a patient’s annual stroke risk using appropriate stroke risk assessment tools and integrating additional stroke risk factors for shared decision-making.
Design evidence-based treatment strategies for subclinical atrial fibrillation and atrial high-rate episodes.
Develop tailored antithrombotic strategies for special populations with atrial fibrillation.
Design an individualized, evidence-based therapeutic plan for patients with atrial fibrillation, including lifestyle and risk factor modifications, and rate and rhythm control strategies.
Chapter: Cardiometabolic and Lifestyle Interventions for Atrial Fibrillation ACPE #: 0217-9999-26-244-H01-P
Evaluate the effect of cardiometabolic risk factors on the development, progression, and management of atrial fibrillation (AF).
Compare the benefits of lifestyle modifications and pharmacologic interventions for the prevention and management of AF.
Assess the risks and limitations of certain pharmacologic therapies that require caution in patients with AF.
Critically evaluate the evidence supporting the use of dapagliflozin, metformin, and colchicine in patients with AF.
Develop evidence-based recommendations for the management of AF and associated comorbid conditions.
Chapter: Atrial Arrhythmias: Rhythm Control and Ambulatory Monitoring ACPE #: 0217-9999-26-251-H01-P
Evaluate patients for the presence of atrial arrhythmias, and assess the potential benefits of a rhythm control strategy.
Evaluate the risk-benefit of different drug therapies according to efficacy, pharmacokinetic properties, and adverse effects.
Evaluate the use of different ablation strategies for atrial arrhythmias and understand medication use associated with the procedure.
Case Series: Bleeding Mitigation in Patients with Atrial Fibrillation ACPE #: 0217-9999-26-252-H01-P
Apply bleeding risk stratification tools for patients with atrial fibrillation (AF) receiving anticoagulation (AC).
Develop strategies to reduce bleeding in high-risk patients with AF receiving AC.
Devise appropriate timing for resuming AC after bleeding to preventing thrombotic events while minimizing rebleeding.
Develop an antithrombotic management plan after a percutaneous left atrial appendage occlusion.
Justify the development or expansion of an inpatient antithrombotic stewardship service.
Design a comprehensive antithrombotic stewardship program incorporating multidisciplinary collaboration and evidence-based strategies.
Evaluate the clinical and economic impact of antithrombotic stewardship programs using data collection, tracking, and outcome measurement.
Evaluate patient-specific clinical data to formulate individualized antithrombotic therapy plans balancing thrombotic and bleeding risks.
Identify strategies to enhance patient and clinician education and awareness to optimize the implementation and impact of antithrombotic stewardship services.
Chapter: Biostatistics and Literature Evaluation in Antithrombotic Clinical Studies ACPE #: 0217-9999-26-254-H01-P
Evaluate how study design choices influence the interpretation and applicability of antithrombotic study findings.
Assess the clinical relevance, sensitivity, and limitations of commonly used clinical end points in antithrombotic research.
Distinguish between different types of biases that may affect antithrombotic studies and methods to control bias in observational studies.
Apply study findings to determine the best therapy for a patient with an indication for antithrombotic therapies.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies:Cynthia Jackevicius (AHA, CSHP); Pamela B. Simone(Novartis;Precision AQ); Christina Ruggia-Check(MJH LifeSciences); Megan Labreck(BostonScientific); Rachel Lavelle(Esperion Therapeutics; Cytokinetics)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.